Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Lantto

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer ModelsDavid M Francis, Shyhmin Huang, Eric A Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2015
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and PlasticityHelle J Jacobsen, Thomas T Poulsen, Anna Dahlman, et al.
Investigational New Drugs|February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignanciesJordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Journal of Molecular Biology|March 28, 2006
Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairingPer-Johan Meijer, Peter S Andersen, Margit Haahr Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2026
Sym024 interacts with a unique epitope on the CD73 homodimer, favoring effective bivalent binding to improve anti-PD1 therapyJanus S Jakobsen, Michael M Grandal, Randi W Hansen, et al.
Mabs|May 4, 2019
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platformTorben Gjetting, Monika Gad, Camilla Fröhlich, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Sym015: A Highly Efficacious Antibody Mixture against <i>MET</i>-Amplified TumorsThomas Tuxen Poulsen, Michael Monrad Grandal, Niels Jørgen Østergaard Skartved, et al.
Molecular Cancer Therapeutics|August 13, 2017
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple MechanismsMichael M Grandal, Serhiy Havrylov, Thomas T Poulsen, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer ModelsDavid M Francis, Shyhmin Huang, Eric A Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2015
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and PlasticityHelle J Jacobsen, Thomas T Poulsen, Anna Dahlman, et al.
Investigational New Drugs|February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignanciesJordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Journal of Molecular Biology|March 28, 2006
Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairingPer-Johan Meijer, Peter S Andersen, Margit Haahr Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2026
Sym024 interacts with a unique epitope on the CD73 homodimer, favoring effective bivalent binding to improve anti-PD1 therapyJanus S Jakobsen, Michael M Grandal, Randi W Hansen, et al.
Mabs|May 4, 2019
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platformTorben Gjetting, Monika Gad, Camilla Fröhlich, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Sym015: A Highly Efficacious Antibody Mixture against <i>MET</i>-Amplified TumorsThomas Tuxen Poulsen, Michael Monrad Grandal, Niels Jørgen Østergaard Skartved, et al.
Molecular Cancer Therapeutics|August 13, 2017
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple MechanismsMichael M Grandal, Serhiy Havrylov, Thomas T Poulsen, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Pageof 4